Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA. There are currently very few options for BTC patients as most cases are at an advanced stage at the time of diagnosis.

Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #LRRK2--Neuron23 is using a Roche-developed digital biomarker as the primary endpoint in the Phase 2 NEULARK trial of NEU-411 in early Parkinson's disease.

Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today that its portfolio company, Flare Therapeutics Inc., has entered into a strategic discovery collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY). Flare will lead discovery and preclinical activities targeting multiple transcription factor targets in oncology, while Roche will pursue the further preclinical and clinical development and commercialization of potential products from the collaboration, leveragin.

Flare Therapeutics Inc., a GordonMD® Global Investments LP Portfolio Company, Enters Strategic Discovery Collaboration with Roche

Merck

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The Global Immunology Biosimilars market showcased growth at a CAGR of 17.92% during 2020-2023. The market was valued at USD 8.03 billion in 2023 which is expected to reach USD 16.22 billion in 2030. This report provides an analysis for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The global Immunology Biosimilars market is expected to witness strong growth during the forecast period, driven by multiple factors. A key factor is the rising incidence of chronic immunological conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which is fueling the demand for cost-effective treatment solutions. As affordable alternatives to branded biologics, biosimilars are gaining significant traction, especially in regions with well-established healthcare systems and expanding patient populations. Another major growth driver is the expiration of patents on blockbuster biologic drugs, opening the door for biosimilars to enter the market. This trend is particularly evident in developed markets like Europe and the Americas, where governments are promoting the use of biosimilars through favorable regulatory policies aimed at lowering healthcare costs. In addition, the expansion of healthcare infrastructure in emerging markets, notably in the Asia Pacific region, is facilitating wider access to advanced therapies, boosting the demand for immunology biosimilars. Rising awareness of biosimilars and government-led initiatives are also expected to further stimulate market growth. Moreover, leading industry players are increasingly focusing on strategic partnerships and ramping up investments in research and development to enhance their product offerings and expand their market reach, driving the market's continued expansion. Scope of the Report

Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,.

Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules aimed at transcription factor targets in oncology Flare Therapeutics to receive US$70 million upfront, and potential milestone payments exceeding US$1.8 billion, as well as royalties CAMBRIDGE, Mass. , Nov. 12, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced it has entered into a strategic discovery collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY).

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

AbbVie

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a better bang for their buck right now?

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held 7-10 December 2024 in San Diego, US. The data underscore Roche's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab) as well as new investigational combination data. Key presentations include:

Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024 in San Diego, California. The data underscore Genentech's commitment to advance patient outcomes in lymphoma with long-term follow-up of its approved medicines Polivy® (polatuzumab vedotin-pii.

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024

PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA's approval of Inavolisib in the U.S. on October 10, 2024.

PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche's Phase III Itovebi Breast Cancer Trial

Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Antibody-Drug Conjugates (ADC) Technology Research and Global Markets Report 2024-2025 & 2029 with Profiles of Leading Players - F. Hoffmann-La Roche.

Roche Holding AG (OTCQX:RHHBY) Virtual Neurology Investor Event Conference October 31, 2024 11:00 AM ET Company Participants Bruno Eschli – Investor Relations Azad Bonni – Senior Vice President and Global Head-Neuroscience and Rare Diseases-pRED Luka Kulic – Therapeutic Area Leader-Dementia and Expert Medical Director-Neuroscience and Rare Diseases-pRED Margherita Carboni – Indication Lead, Neurology and Clinical Development Lead-Neurology, Endocrinology and OBGYN-Roche Diagnostics Hanno Svoboda – Head-Portfolio Development and Neuroscience and Rare Diseases Conference Call Participants Richard Parkes – BNP Paribas Sachin Jain – Bank of America Colin White – UBS David Evans – Kepler Luisa Hector – Berenberg Richard Vosser – JPMorgan Rajesh Kumar – HSBC Colin White – UBS Bruno Eschli [Call Starts Abruptly] Thanks Henrik, for the introduction. Can we please go to the agenda slide, please?

Roche Holding AG (RHHBY) Virtual Neurology Investor Event Conference Transcript

Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4) , for Alzheimer's disease, at the 17th Clinical Trials in Alzheimer's Disease congress (CTAD) in Madrid, Spain. Results show that the test, currently in development, could accurately rule out amyloid pathology – a hallmark of Alzheimer's disease – in a broad population with varying cognitive impairment, as seen in routine clinical practice.1 This could allow clinicians to rule out Alzheimer's disease as a possible cause of cognitive symptoms with a simple blood test, offering certainty and reassurance.

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's disease

Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the positive phase III INAVO120 results, evaluating ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant were published in the New England Journal of Medicine.1 The United States Food and Drug Administration (FDA) recently approved Itovebi in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. Data from INAVO120 are also being used for filing submissions to other global health authorities, including the European Medicines Agency.

New England Journal of Medicine publishes landmark phase III results for Roche's Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the positive Phase III INAVO120 results, evaluating ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant was published in the New England Journal of Medicine. The U.S. Food and Drug Administration (FDA) recently approved Itovebi in combination with palbociclib and fulvestrant, for the treatment of adults with.

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech's Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer

Roche's strong year-to-date results are masked by the strength of the Swiss franc and are also impacted by declining COVID-19 sales, but underlying growth trends are strong. Key products like Vabysmo, Ocrevus, and Phesgo are performing well. The pipeline remains healthy with upcoming readouts from mid- and late-stage trials of (among others) tiragolumab, GYM329, and fenebrutinib.

Roche: Currency Headwinds Are Masking Strong Growth Trends

WATERTOWN, Mass.--(BUSINESS WIRE)--New strategic partnership leverages the power of Dyno's platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets.

Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases

Roche Holding AG (RHHBY) Q3 2024 Sales/Trading Statement Call

RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.

Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024

Roche stock was unmoved early Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.

Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations

Catalent

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers.

Roche comes out against clearing takeover of drug manufacturer Catalent

The CEO of Roche said more cases of mpox infection have likely occurred in Europe than previously reported and that the group could quickly offer 10 times more test kits than are currently in demand.

Roche CEO says more mpox cases likely to be reported in Europe

Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus lifted sales in the first nine months of the year.

Roche Increases Dividend on Higher Sales

Roche on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion).

Roche Q3 sales advance by forex-adj 9%, beating market view

Roche CEO Thomas Schinecker: “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients' lives around the world.

[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

News for Roche Holding AG Stock (RHHBY)